ProPhase Labs, Inc. Stock

$0.28

9.77% yesterday

Nasdaq, Aug 11, 10:15 pm CET

ISIN

US74345W1080

Symbol

PRPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

ProPhase Labs, Inc. Stock price

$0.28

-2.01 87.70% 5Y

Nasdaq, Closing price Mon, Aug 11 2025

-0.03 9.77%

ISIN

US74345W1080

Symbol

PRPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$11.7m

Enterprise Value

$20.5m

Net debt

$8.8m

Cash

$90.0k

Shares outstanding

41.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

1.7 | 0.6

EV/Sales

2.9 | 1.0

EV/FCF

negative

P/B

0.8

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | -22.8%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$7.1m | $21.8m

EBITDA

$-12.9m | $19.3m

EBIT

$-19.4m | $-10.5m

Net Income

$-8.8m | $-23.7m

Free Cash Flow

$-15.8m

Growth (TTM | estimate)

Revenue

-75.5% | 221.8%

EBITDA

46.6% | 160.4%

EBIT

36.9% | 72.8%

Net Income

62.8% | 55.5%

Free Cash Flow

10.5%

Financial Health

Equity Ratio

11.6%

Return on Equity

-725.7%

ROCE

-74.6%

ROIC

-47.7%

Debt/Equity

0.6

EPS

$-0.2

FCF per Share

$-0.4

Short interest

0.4%

Employees

Rev per Employee

$70.0k

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

ProPhase Labs, Inc. Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a ProPhase Labs, Inc. forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a ProPhase Labs, Inc. forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from ProPhase Labs, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	7.05 7.05	75% 75% 100%
- Direct Costs	7.17 7.17	69% 69% 102%
Gross Profit	-0.12 -0.12	102% 102% -2%
- Selling and Administrative Expenses	19 19	44% 44% 269%
- Research and Development Expense	0.36 0.36	77% 77% 5%
EBITDA	-13 -13	47% 47% -183%
- Depreciation and Amortization	6.56 6.56	2% 2% 93%
EBIT (Operating Income) EBIT	-19 -19	37% 37% -276%
Net Profit	-8.77 -8.77	63% 63% -124%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ProPhase Labs, Inc. Stock News

Neutral

GlobeNewsWire

●

about 21 hours ago

ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025

UNIONDALE, NY, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, announced today that they will be presenting second quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. A press release detailing these results...

Neutral

GlobeNewsWire

●

14 days ago

ProPhase Labs Announces Special Meeting of Shareholders and Filing of Preliminary Proxy Statement

Proxy Sets Company on a Path to Attract the Optimal Crypto Treasury Strategy Increase in Authorized Shares to 1 Billion Would Position the Company to Attract Industry-Leading Market Participants and High-Value Crypto Treasury Transactions UNIONDALE, NY, July 29, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and con...

Neutral

GlobeNewsWire

●

20 days ago

ProPhase Labs Announces Closing of $3 Million Senior Secured Convertible Notes Financing

Financing provides bridge to multiple potentially significant liquidity events and crypto strategies UNIONDALE, NY, July 23, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the "Company" or "ProPhase") today announced the closing of a private placement financing with two investors for $3 million in senior secured convertible notes with accompanying warrants to purchase shares of c...

More ProPhase Labs, Inc. News

Company Profile

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer consumer healthcare products and dietary supplements. Its products include TK supplement. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Doylestown, PA.

Head office	United States
CEO	Ted Karkus
Employees	96
Founded	1989
Website	www.prophaselabs.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now